Arcus Biosciences

RCUS

Market cap $1.23B

Overview Fund Activity

11.52 USD

+0.02

0.17%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

11.52

0.00

0%

1 day

0.17%

5 days

-5.65%

1 month

19.13%

3 months

23.21%

6 months

18.76%

Year to date

-23.86%

1 year

-33.76%

5 years

-49.89%

10 years

-32.24%

About: Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Employees: 674

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,644% more call options, than puts

Call options by funds: $26.4M | Put options by funds: $1.52M

73% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 49

6% more capital invested

Capital invested by funds: $763M [Q1] → $811M (+$48.1M) [Q2]

2.32% more ownership

Funds ownership: 91.85% [Q1] → 94.18% (+2.32%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 26

2% less funds holding

Funds holding: 186 [Q1] → 183 (-3) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$25

117% upside

Avg. target

$25

117% upside

High target

$25

117% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Wells Fargo

Eva Fortea Verdejo

$25

Overweight

Maintained

7 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about RCUS published over the past 30 days

Arcus Biosciences, Inc. (RCUS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Arcus Biosciences, Inc. (NYSE:RCUS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Jennifer Jarrett - Chief Operating Officer Richard Markus - Chief Medical Officer Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Good morning.

Arcus Biosciences, Inc. (RCUS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 19,300 shares of the Company's common stock at an exercise price per share of $12.19, which was the closing price on September 8, 2025, a.

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (RCUS) Presents At Citi's Biopharma Back To School Conference Transcript

Arcus Biosciences, Inc. (NYSE:RCUS ) Citi's Biopharma Back to School Conference September 3, 2025 11:15 AM EDT Company Participants Terry Rosen - Co-Founder, Chairman & CEO Jennifer Jarrett - Chief Operating Officer Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst So welcome, everyone. I'm Yigal Nochomovitz, Biotech Analyst at Citi.

Arcus Biosciences, Inc. (RCUS) Presents At Citi's Biopharma Back To School Conference Transcript

Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS) announced today that it will host an in-person and virtual Investor Event for analysts and investors on Monday, October 6, 2025, beginning at 10:00 AM ET, in New York City. The event will highlight new data for Arcus's HIF-2a inhibitor casdatifan from the monotherapy cohorts of the Phase 1b ARC-20 trial in late-line clear cell renal cell carcinoma (ccRCC). Featured presenters will include members of the Arcus management team and ke.

Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in September: Citi's 2025 Biotech Back to School Conference Date: Wednesday, September 3rd, 2025 Location: Boston, MA Format: Fireside chat & 1x1 meetings Time: 11:15 a.m. ET H.C. W.

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Uranium Energy Corp. UEC, saying, “I like nuclear.”

Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus

Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months

Arcus Biosciences is at a critical juncture, with multiple late-stage assets and a cash position nearly equal to its market cap. Casdatifan shows best-in-class potential in renal cell carcinoma, with pivotal Phase 3 data expected within 12 months to determine commercial viability. Ongoing Phase 3 studies for domvanalimab and quemliclustat offer significant catalysts, with key data readouts anticipated in 2026.

Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months

The Motley Fool

Arcus (RCUS) Q2 Revenue Jumps 310%

Arcus (RCUS) Q2 Revenue Jumps 310%

Arcus (RCUS) Q2 Revenue Jumps 310%

Zacks Investment Research

Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2

Arcus Biosciences, Inc. (RCUS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $1.02 per share a year ago.

Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a pipeline update on its clinical-stage investigational molecules across multiple common cancers. “We have now presented data from over 125 patients treated with casdatifan monotherapy or.

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

See News Rankings

Charts implemented using Lightweight Charts™